Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) EBIT Margin (2016 - 2025)

Historic EBIT Margin for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to 83.06%.

  • China Pharma Holdings' EBIT Margin rose 155800.0% to 83.06% in Q3 2025 from the same period last year, while for Sep 2025 it was 79.83%, marking a year-over-year increase of 27200.0%. This contributed to the annual value of 101.32% for FY2024, which is 620800.0% down from last year.
  • China Pharma Holdings' EBIT Margin amounted to 83.06% in Q3 2025, which was up 155800.0% from 63.57% recorded in Q2 2025.
  • China Pharma Holdings' 5-year EBIT Margin high stood at 20.28% for Q1 2023, and its period low was 150.44% during Q2 2024.
  • Its 5-year average for EBIT Margin is 57.54%, with a median of 48.33% in 2022.
  • Its EBIT Margin has fluctuated over the past 5 years, first plummeted by -1088800bps in 2024, then soared by 868700bps in 2025.
  • Quarter analysis of 5 years shows China Pharma Holdings' EBIT Margin stood at 22.45% in 2021, then tumbled by -78bps to 40.02% in 2022, then plummeted by -38bps to 55.1% in 2023, then tumbled by -91bps to 105.47% in 2024, then increased by 21bps to 83.06% in 2025.
  • Its EBIT Margin was 83.06% in Q3 2025, compared to 63.57% in Q2 2025 and 66.76% in Q1 2025.